Top Midday Gainers

MT Newswires Live03-10

Relmada Therapeutics (RLMD) said Monday it has struck a deal to sell shares and pre-funded warrants to investors, including Venrock Healthcare Capital Partners and Commodore Capital, to raise about $160 million. It expects to close the deal March 11.

Shares soared 46% as intraday trading volume surged to over 36.4 million from a daily average of about 676,000.

Dianthus Therapeutics (DNTH) said early Go decision was reached in phase 3 trial of claseprubart in chronic inflammatory demyelinating polyneuropathy after 20 confirmed responders were achieved with less than 40 planned participants completing open-label part A of the trial. The firm also reported Q4 results.

Shares jumped 18% as intraday trading volume climbed to more than 3.2 million from a daily average of about 795,000.

Xenon Pharmaceuticals (XENE) reported "positive" topline results from its phase 3 study of azetukalner in focal onset seizures.

Shares soared 46% as intraday trading volume jumped to over 9.5 million from a daily average of roughly 917,000.

Price: 6.65, Change: +2.20, Percent Change: +49.33

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2618894679?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-10 02:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2618894679","market":"fut","top_or_hot":-1,"title":"Top Midday Gainers","media":"MT Newswires Live","content":"<html><body><p> Relmada <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (RLMD) said Monday it has struck a deal to sell shares and pre-funded warrants to investors, including Venrock Healthcare Capital Partners and Commodore Capital, to raise about $160 million. It expects to close the deal March 11.</p><p>Shares soared 46% as intraday trading volume surged to over 36.4 million from a daily average of about 676,000.</p><p>Dianthus Therapeutics (DNTH) said early Go decision was reached in phase 3 trial of claseprubart in chronic inflammatory demyelinating polyneuropathy after 20 confirmed responders were achieved with less than 40 planned participants completing open-label part A of the trial. The firm also reported Q4 results.</p><p>Shares jumped 18% as intraday trading volume climbed to more than 3.2 million from a daily average of about 795,000.</p><p>Xenon Pharmaceuticals (XENE) reported \"positive\" topline results from its phase 3 study of azetukalner in focal onset seizures.</p><p>Shares soared 46% as intraday trading volume jumped to over 9.5 million from a daily average of roughly 917,000.</p><p>Price: 6.65, Change: +2.20, Percent Change: +49.33</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Top Midday Gainers</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTop Midday Gainers\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-03-10 02:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Relmada <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (RLMD) said Monday it has struck a deal to sell shares and pre-funded warrants to investors, including Venrock Healthcare Capital Partners and Commodore Capital, to raise about $160 million. It expects to close the deal March 11.</p><p>Shares soared 46% as intraday trading volume surged to over 36.4 million from a daily average of about 676,000.</p><p>Dianthus Therapeutics (DNTH) said early Go decision was reached in phase 3 trial of claseprubart in chronic inflammatory demyelinating polyneuropathy after 20 confirmed responders were achieved with less than 40 planned participants completing open-label part A of the trial. The firm also reported Q4 results.</p><p>Shares jumped 18% as intraday trading volume climbed to more than 3.2 million from a daily average of about 795,000.</p><p>Xenon Pharmaceuticals (XENE) reported \"positive\" topline results from its phase 3 study of azetukalner in focal onset seizures.</p><p>Shares soared 46% as intraday trading volume jumped to over 9.5 million from a daily average of roughly 917,000.</p><p>Price: 6.65, Change: +2.20, Percent Change: +49.33</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DNTH","symbol_name":"Dianthus Therapeutics Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2618894679","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2618894679","pubTimestamp":1773081760,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Relmada Therapeutics  said Monday it has struck a deal to sell shares and pre-funded warrants to investors, including Venrock Healthcare Capital Partners and Commodore Capital, to raise about $160 million. It expects to close the deal March 11.Shares soared 46% as intraday trading volume surged to over 36.4 million from a daily average of about 676,000.Dianthus Therapeutics  said early Go decision was reached in phase 3 trial of claseprubart in chronic inflammatory demyelinating polyneuropathy after 20 confirmed responders were achieved with less than 40 planned participants completing open-label part A of the trial. The firm also reported Q4 results.Shares jumped 18% as intraday trading volume climbed to more than 3.2 million from a daily average of about 795,000.Xenon Pharmaceuticals  reported \"positive\" topline results from its phase 3 study of azetukalner in focal onset seizures.Shares soared 46% as intraday trading volume jumped to over 9.5 million from a daily average of roughly ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"DNTH":"Dianthus Therapeutics Inc.","XENE":"Xenon制药","BK4139":"生物科技","BK4007":"制药","RLMD":"Relmada Therapeutics, Inc."},"translate_title":"午盘涨幅最大的股票","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RLMD":1,"XENE":1,"DNTH":1},"content_text":"Relmada Therapeutics (RLMD) said Monday it has struck a deal to sell shares and pre-funded warrants to investors, including Venrock Healthcare Capital Partners and Commodore Capital, to raise about $160 million. It expects to close the deal March 11.Shares soared 46% as intraday trading volume surged to over 36.4 million from a daily average of about 676,000.Dianthus Therapeutics (DNTH) said early Go decision was reached in phase 3 trial of claseprubart in chronic inflammatory demyelinating polyneuropathy after 20 confirmed responders were achieved with less than 40 planned participants completing open-label part A of the trial. The firm also reported Q4 results.Shares jumped 18% as intraday trading volume climbed to more than 3.2 million from a daily average of about 795,000.Xenon Pharmaceuticals (XENE) reported \"positive\" topline results from its phase 3 study of azetukalner in focal onset seizures.Shares soared 46% as intraday trading volume jumped to over 9.5 million from a daily average of roughly 917,000.Price: 6.65, Change: +2.20, Percent Change: +49.33","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.38.0","shortVersion":"4.38.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2618894679","isCrawlerRequest":true}